Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Drugs Acting on Autonomic Ganglia: Stimulants01:23

Drugs Acting on Autonomic Ganglia: Stimulants

2.2K

Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Community-Acquired Pneumococcal Ventriculitis as a Complication of Otogenic Pneumococcal Meningitis: A Case Report.

Case reports in infectious diseases·2026
Same author

Phase-targeted auditory stimulation enhances slow-wave activity during sleep in Huntington's disease: A pilot crossover study.

Journal of Huntington's disease·2026
Same author

Novel YWHAE-NTRK3 fusion in a pediatric glioma.

Journal of neuropathology and experimental neurology·2026
Same author

Sodium channel blockers are associated with reduced dementia risk in late-onset unexplained epilepsy.

medRxiv : the preprint server for health sciences·2026
Same author

A machine learning-derived speech index as a biomarker for Huntington's disease severity.

Journal of neurology·2026
Same author

Association between aldehyde dehydrogenase 4 family member A1 plasma concentrations and atherosclerotic disease in patients with ischemic stroke: Results from the prospective multicenter BIOSIGNAL study.

Clinica chimica acta; international journal of clinical chemistry·2026

Related Experiment Video

Updated: Mar 13, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.6K

Exercise effects in Huntington disease.

Sebastian Frese1,2, Jens A Petersen1, Maria Ligon-Auer1

  • 1Department of Neurology, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland.

Journal of Neurology
|October 18, 2016
PubMed
Summary

Endurance training (ET) helped stabilize motor function and improve cardiovascular health in Huntington disease (HD) patients. This exercise intervention shows promise as a therapeutic strategy for managing HD progression.

Keywords:
Cardiovascular functionEndurance trainingMotor functionPeak oxygen uptake ()Unified Huntington disease rating scale (UHDRS)

More Related Videos

The 6-hydroxydopamine Rat Model of Parkinson's Disease
08:10

The 6-hydroxydopamine Rat Model of Parkinson's Disease

Published on: October 27, 2021

13.4K
Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice
08:27

Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice

Published on: March 11, 2020

6.7K

Related Experiment Videos

Last Updated: Mar 13, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.6K
The 6-hydroxydopamine Rat Model of Parkinson's Disease
08:10

The 6-hydroxydopamine Rat Model of Parkinson's Disease

Published on: October 27, 2021

13.4K
Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice
08:27

Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice

Published on: March 11, 2020

6.7K

Area of Science:

  • Neuroscience
  • Exercise Physiology
  • Clinical Medicine

Background:

  • Huntington disease (HD) is a progressive neurodegenerative disorder affecting cognitive and motor functions.
  • No causative treatment exists for HD, but lifestyle factors may influence disease progression.
  • The specific benefits of exercise for HD patients remain under investigation.

Purpose of the Study:

  • To investigate the effects of 26 weeks of endurance training (ET) on motor and cognitive function in HD patients.
  • To assess the impact of ET on cardiovascular function in individuals with HD.
  • To determine if ET can serve as a therapeutic strategy for Huntington disease.

Main Methods:

  • Twelve male HD patients and twelve male controls underwent 26 weeks of endurance training.
  • Clinical assessments, exercise physiology tests, and body composition measurements were performed pre- and post-training.
  • Muscle biopsies were collected from the M. vastus lateralis.

Main Results:

  • Endurance training led to stabilization of motor deficits in HD patients, as measured by the Unified Huntington's Disease Rating Scale.
  • Peak oxygen uptake significantly increased in both HD patients and controls following the training intervention.
  • No adverse effects were reported during the endurance training program.

Conclusions:

  • Endurance training is a viable therapeutic strategy for Huntington disease patients.
  • Exercise can improve cardiovascular function and stabilize motor function in individuals with HD.
  • HD patients are amenable to exercise-induced improvements, supporting its role in disease management.